Key points of heart failure in some special situations

Versions

PDF (Español (España))
Texto (Español (España))

Keywords

Insuficiencia cardíaca
tuberculosis diabetes mellitus
insuficiencia renal crónica
fibrilación atrial
deficiencia de hierro Heart failure
diabetes mellitus
renal insufficiency
atrial fibrillation
iron deficiencies

How to Cite

Aristizabal, D., Valencia Garcia , M. ., & Weir Restrepo , D. (2023). Key points of heart failure in some special situations. Interdisciplinary Journal of Epidemiology and Public Health, 5(2), e–9883. https://doi.org/10.18041/2665-427X/ijeph.2.9883 (Original work published December 30, 2022)

Abstract

Introduction: Heart failure (HF) is a highly prevalent pathology worldwide, its proper diagnosis and management is essential to reduce and/or control its morbidity, however, its treatment not only goes hand in hand with the pathology itself, as the optimization of some of the diseases that usually surround this pathology directly impacts on the course of the disease.

Methods: A Narrative review of the literature was carried out.

Results: In patients with HF with preserved ejection fraction, iSGLT-2 are the only drugs that have shown to be useful in this subpopulation regardless of their comorbid state with diabetes; moreover, in patients with HF with reduced fraction with or without diabetes, their initiation can be performed early after discharge, generating an impact on the outcomes of major cardiovascular disease (MACE), hospitalization and mortality. As for chronic kidney disease, the drugs used in HF are no longer considered nephrotoxic, since their use, although it produces a reduction of the Glomerular Filtration Rate (GFR) in the long term, delays deterioration and improves prognosis. In addition, the adequate management of iron deficiency and atrial fibrillation reduces adverse outcomes and improves quality of life.

Conclusions: timely management of type 2 diabetes mellitus and chronic renal disease is essential to control the progression of heart failure, as well as therapeutics such as the use of iron carboxymaltose and the adequate therapeutic approach to atrial fibrillation are determinant to reduce adverse outcomes and improve quality of life.

https://doi.org/10.18041/2665-427X/ijeph.2.9883
PDF (Español (España))
Texto (Español (España))

References

Ciapponi A, Alcaraz A, Calderón M, Matta MG, Chaparro M, Soto N, et al. Burden of heart failure in Latin America: a systematic review and meta-analysis. Rev Esp Cardiol Engl Ed. 2016; 69: 1051-60. Doi: 10.1016/j.rec.2016.04.054.

Gómez-Mesa JE, Saldarriaga-Giraldo CI, Echeverría LE, Luna P, Recolfaca GI. Registro colombiano de falla cardiaca (RECOLFACA): metodología y datos preliminares. Rev Colomb Cardiol. 2021; 28(3):217-230. Doi: 10.24875/RCCAR.M21000021.

Chopra VK, Anker SD. Anaemia, iron deficiency and heart failure in 2020: facts and numbers. ESC Heart Fail. 2020; 7: 2007-11. Doi: 10.1002/ehf2.12797.

Becher PM, Schrage B, Benson L, Fudim M, Corovic Cabrera C, Dahlström U, et al. Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry. Eur J Heart Fail. 2021;23:1844-54. Doi: 10.1002/ejhf.2338.

Bauersachs J. Heart failure drug treatment: the fantastic four. Eur Heart J. 2021;42:681-3. Doi: 10.1093/eurheartj/ehaa1012.

Kristensen SL, Preiss D, Jhund PS, Squire I, Cardoso JS, Merkely B, et al. Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction. Circ Heart Fail. 2016;9:e002560. Doi: 10.1161/CIRCHEARTFAILURE.115.002560.

Zapatero-Gaviria A, Gómez-Huelgas R, Canora-Lebrato J, Ena-Muñoz J, Romero-Sánchez M, Mendez-Bailón M, et al. Análisis de las hospitalizaciones por enfermedad cardiovascular en población diabética en España. Rev Clínica Esp. 2019;219:124-9. Doi: 10.1016/j.rce.2018.09.012.

McMurray JJV, Gerstein HC, Holman RR, Pfeffer MA. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol. 2014;2:843-51. Doi: 10.1016/S2213-8587(14)70031-2.

Zelniker TA, Braunwald E. Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75:422-34. Doi: 10.1016/j.jacc.2019.11.031.

Staplin N, Roddick AJ, Emberson J, Reith C, Riding A, Wonnacott A, et al. Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials. EClinicalMedicine. 2021;41: 101163. Doi: 10.1016/j.eclinm.2021.101163.

Kristensen SL, Rørth R, Jhund PS, Docherty KF, Sattar N, Preiss D, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7:776-85. Doi: 10.1016/S2213-8587(19)30249-9.

McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995-2008. Doi: 10.1056/NEJMoa1911303.

Jering KS, Claggett B, Pfeffer MA, Granger C, Køber L, Lewis EF, et al. Prospective ARNI vs. ACE inhibitor trial to determIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics. Eur J Heart Fail. 2021;23:1040-8. Doi: 10.1002/ejhf.2191.

Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med. 2021; 384: 117-28. Doi: 10.1056/NEJMoa2030183.

Le VT, Perez-Moreno AC, Calderone P, Epstein J, Muhlestein JB, Knowlton KU, et al. Combined therapy with sodium-glucose cotransporter-2 inhibitors (sglt2i) and glucagon-like peptide-1 receptor agonists (glp1-ra)—tolerability and clinical impact: the intermountain healthcare real world experience. J Am Coll Cardiol. 2022;79:1443-1443. Doi: 10.1016/S0735-1097(22)02434-2.

Li C, Luo J, Jiang M, Wang K. The efficacy and safety of the combination therapy with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes mellitus: a systematic review and meta-analysis. Front Pharmacol. 2022;13: 838277. doi: 10.3389/fphar.2022.838277.

Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451-61. Doi: 10.1056/NEJMoa2107038.

Mullens W, Martens P, Testani JM, Tang WHW, Skouri H, Verbrugge FH, et al. Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2022;24:603-19. Doi: 10.1002/ejhf.2471.

Clark AL, Kalra PR, Petrie MC, Mark PB, Tomlinson LA, Tomson CR. Change in renal function associated with drug treatment in heart failure: national guidance. Heart. 2019;105:904-10. Doi: 10.1136/heartjnl-2018-314158.

Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J. 2010;31:1872-80. Doi: 10.1093/eurheartj/ehq158.

Jankowska EA, Tkaczyszyn M, Suchocki T, Drozd M, von Haehling S, Doehner W, et al. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials: Intravenous iron therapy in systolic heart failure. Eur J Heart Fail. 2016;18:786-95. Doi: 10.1002/ejhf.473.

Anand IS, Gupta P. Anemia and iron deficiency in heart failure: current concepts and emerging therapies. Circulation. 2018;138:80-98. Doi: 10.1161/CIRCULATIONAHA.118.030099.

Ponikowski P, Kirwan B-A, Anker SD, McDonagh T, Dorobantu M, Drozdz J, et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet. 2020;396:1895-904. Doi: 10.1016/S0140-6736(20)32339-4.

López-Vilella R, Lozano-Edo S, Arenas MP, Jover-Pastor P, Ezzitouny M, Sorolla Romero J, et al. Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction. ESC Heart Fail. 2022;9:133-45. Doi: 10.1002/ehf2.13753.

Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79:e263-421. Doi: 10.1016/j.jacc.2021.12.012.

Lardizabal JA, Deedwania PC. Atrial fibrillation in heart failure. Med Clin North Am. 2012;96:987-1000. Doi: 10.1016/j.mcna.2012.07.007.

Carlisle MA, Fudim M, Devore AD, Piccini JP. Heart failure and atrial fibrillation, like fire and fury. JACC Heart Fail. 2019; 7(6): 447-456. doi: 10.1016/j.jchf.2019.03.005.

Verma A, Kalman JM, Callans DJ. Treatment of patients with atrial fibrillation and heart failure with reduced ejection fraction. Circulation. 2017;135:1547-63. Doi: 10.1161/CIRCULATIONAHA.116.026054.

Samet P, Bernstein W, Levine S. Significance of the atrial contribution to ventricular filling. Am J Cardiol. 1965;15:195-202. Doi: 10.1016/0002-9149(65)90454-6.

Solti F, Vecsey T, KékesI V, Juhász-Nagy A. The effect of atrial dilatation on the genesis of atrial arrhythmias. Cardiovasc Res. 1989;23:882-6. Doi: 10.1093/cvr/23.10.882.

Boos CJ, Anderson RA, Lip GYH. Is atrial fibrillation an inflammatory disorder? Eur Heart J. 2006;27:136-49. Doi: 10.1093/eurheartj/ehi645.

Hu Y-F, Chen Y-J, Lin Y-J, Chen S-A. Inflammation and the pathogenesis of atrial fibrillation. Nat Rev Cardiol. 2015;12:230-43. Doi: 10.1038/nrcardio.2015.2.

Negi S, Shukrullah I, Veledar E, Bloom HL, Jones DP, Dudley SC. Statin Therapy for the Prevention of Atrial Fibrillation Trial (SToP AF trial). J Cardiovasc Electrophysiol. 2011;22:414-9. Doi: 10.1111/j.1540-8167.2010.01925.x.

Bang CN, Greve AM, Abdulla J, Køber L, Gislason GH, Wachtell K. The preventive effect of statin therapy on new-onset and recurrent atrial fibrillation in patients not undergoing invasive cardiac interventions: A systematic review and meta-analysis. Int J Cardiol. 2013;167:624-30. Doi: 10.1016/j.ijcard.2012.08.056.

Sartipy U, Dahlström U, Fu M, Lund LH. Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction. JACC Heart Fail. 2017;5:565-74. Doi: 10.1016/j.jchf.2017.05.001.

Brown LAE, Boos CJ. Atrial fibrillation and heart failure: Factors influencing the choice of oral anticoagulant. Int J Cardiol. 2017;227:863-8. Doi: 10.1016/j.ijcard.2016.09.086.

Sandhu RK, Hohnloser SH, Pfeffer MA, Yuan F, Hart RG, Yusuf S, et al. Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure. Stroke. 2015;46:667-72. Doi: 10.1161/STROKEAHA.114.007140.

Kotecha D, Banerjee A, Lip GYH. Increased stroke risk in atrial fibrillation patients with heart failure. Stroke. 2015;46:608-9. Doi: 10.1161/STROKEAHA.114.008421.

Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, et al. Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure. N Engl J Med 2008;358:2667-77. Doi: 10.1056/NEJMoa0708789.

Camm AJ, Naccarelli GV, Mittal S, Crijns HJGM, Hohnloser SH, Ma C-S, et al. The increasing role of rhythm control in patients with atrial fibrillation: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022;79:1932-48. Doi: 10.1016/j.jacc.2022.03.337.

Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42:373-498. Doi: 10.1093/eurheartj/ehaa612.

Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018;378:417-27. Doi: 10.1056/NEJMoa1707855.

Jones DG, Haldar SK, Hussain W, Sharma R, Francis DP, Rahman-Haley SL, et al. A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. J Am Coll Cardiol. 2013;61:1894-903. Doi: 10.1016/j.jacc.2013.01.069.

Hunter RJ, Berriman TJ, Diab I, Kamdar R, Richmond L, Baker V, et al. A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial). Circ Arrhythm Electrophysiol. 2014;7:31-8. Doi: 10.1161/CIRCEP.113.000806.

Di Biase L, Mohanty P, Mohanty S, Santangeli P, Trivedi C, Lakkireddy D, et al. Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device. Circulation. 2016;133:1637-44. Doi: 10.1161/CIRCULATIONAHA.115.019406.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright (c) 2022 Interdisciplinary Journal of Epidemiology and Public Health

Downloads

Download data is not yet available.